Skip to main content

Onconetix, Inc.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

ONCO$3.47-3.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

Six months Ended June 30, 2025Six months Ended June 30, 2024
Cash flows from operating activities
Net loss$(10,918,327)$(25,425,276)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on impairment of goodwill11,512,00015,453,000
Impairment of ENTADFI assets—3,530,716
Amortization of debt discounts4,966291,959
Amortization of debt discount - related party—293,820
Depreciation and amortization8,447408,001
Net periodic pension benefit107,304(24,868)
Stock-based compensation60,23851,875
Interest accrued on note payable—95,751
Interest accrued on note payable – related party—87,123
Loss on impairment of inventory of ENTADFI—356,637
Change in fair value of contingent warrant liabilities10,024—
Change in fair value of subscription agreement liability – related party(3,127,962)21,600
Gain on forgiveness of accounts payable(944,694)—
Deferred tax benefit—(70,799)
Loss on disposal of property and equipment16,482—
Changes in operating assets and liabilities:
Accounts receivable15,685(31,501)
Inventories(72,765)(159,095)
Prepaid expenses and other current assets201,379(220,928)
Prepaid expenses, long-term—(7,749)
Accounts payable(272,801)(2,188,629)
Accrued expenses(9,952)(893,228)
Net cash used in operating activities(3,409,976)(8,431,591)
Cash flows from investing activities
Purchases of property and equipment—(22,284)
Net cash Provided by (used in) investing activities—(22,284)
Cash flows from financing activities
Proceeds from issuance of note payable – related party—5,000,000
Proceeds from issuance of note payable475,000678,550
Payment of financing costs—(400,000)
Principal payments of notes payable(1,537,331)(417,046)
Payment for redemption of Series C Preferred Stock(1,713,570)—
Proceeds from exercise of stock options—163
Proceeds from purchases of common stock in connection with the ELOC6,391,655—
Cash in lieu of shares(926)—
Net cash provided by financing activities3,614,8284,861,667
Effect of exchange rate changes on cash(567,837)(31,586)
Net decrease in cash(362,985)(3,623,794)
Cash, beginning of period646,5004,554,335
Cash, end of period$283,515$930,541
Supplemental disclosure of cash flow information:
Cash paid for interest$184,546$4,405
Noncash investing and financing activities:
D&O insurance premium financed$460,875$—
Deemed dividend owed to Series C preferred stock shareholders$409,510$—
Establishment of operating right-of-use asset$—$87,864
Settlement of subscription agreement liability$995,038$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.